Does GOLIMUMAB Cause Hepatocellular carcinoma? 7 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hepatocellular carcinoma have been filed in association with GOLIMUMAB (SIMPONI ARIA). This represents 0.0% of all adverse event reports for GOLIMUMAB.
7
Reports of Hepatocellular carcinoma with GOLIMUMAB
0.0%
of all GOLIMUMAB reports
1
Deaths
2
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From GOLIMUMAB?
Of the 7 reports, 1 (14.3%) resulted in death, 2 (28.6%) required hospitalization.
Is Hepatocellular carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GOLIMUMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does GOLIMUMAB Cause?
Drug ineffective (17,959)
Rheumatoid arthritis (12,272)
Pain (11,443)
Fatigue (9,626)
Off label use (8,764)
Alopecia (8,394)
Rash (8,331)
Joint swelling (8,264)
Arthralgia (7,968)
Abdominal discomfort (7,902)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which GOLIMUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
GOLIMUMAB vs GOLODIRSEN
GOLIMUMAB vs GONADORELIN
GOLIMUMAB vs GONADOTROPHIN, CHORIONIC
GOLIMUMAB vs GOSERELIN
GOLIMUMAB vs GRAMICIDIN